Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

inavolisib (GDC-0077)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

PIK3CA inhibitor

Related drugs:

PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	palbociclib + GDC-0077 Sensitive: B - Late Trials palbociclib + GDC-0077 Sensitive : B	palbociclib + GDC-0077 Sensitive: B - Late Trials palbociclib + GDC-0077 Sensitive : B
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	GDC-0077 Sensitive: C2 – Inclusion Criteria GDC-0077 Sensitive : C2	GDC-0077 Sensitive: C2 – Inclusion Criteria GDC-0077 Sensitive : C2
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	GDC-9545 + GDC-0077 Sensitive: C3 – Early Trials GDC-9545 + GDC-0077 Sensitive : C3	GDC-9545 + GDC-0077 Sensitive: C3 – Early Trials GDC-9545 + GDC-0077 Sensitive : C3
MPZL3 overexpression	Breast Cancer	MPZL3 overexpression	Breast Cancer	GDC-0077 Resistant: D – Preclinical GDC-0077 Resistant : D	GDC-0077 Resistant: D – Preclinical GDC-0077 Resistant : D